PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results for the fourth quarter ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients ...

MUSC health has established the Rena N. Grant Sickle Cell Center to help treat those suffering from sickle cell disease. This ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

The Medical University of South Carolina is expanding its access to state-supported Sickle Cell programs for “warriors,” or ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...